Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group [Pediatric Oncology]

Conclusion
Pediatric patients with t(8;21)-AML and additional del(9q) or additional +4 might not be considered at good risk. Patients with t(8;21)-AML likely benefit from protocols that have high doses of anthracyclines, etoposide, and cytarabine during induction, as well as from protocols comprising cumulative high doses of cytarabine and etoposide.

Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Klein, Kaspers, Harrison, Beverloo, Reedijk, Bongers, Cloos, Pession, Reinhardt, Zimmerman, Creutzig, Dworzak, Alonzo, Johnston, Hirsch, Zapotocky, De Moerloose, Fynn, Lee, Taga, Tawa, Auvrignon, Zeller, Forestier, Salgado, Balwierz, Popa, Rubnitz, Raimon Tags: Acute Non-Lymphoblastic Leukemia/MDS/CML Pediatric Oncology Source Type: research